Results 131 to 140 of about 11,312 (241)

Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering. [PDF]

Biomolecules
Bednova O, Pougoue Ketchemen J, Mslati H, Barok M, Joensuu H, Zeytuni N, Gentile F, Sanche L, Fonge H, Leyton JV.   +9 more
europepmc   +1 more source

Seni barok Himmel Auf Reden di Jerman abad 17-19 / Wanda Listiani [PDF]

, 2016
Listiani Wanda
openalex  

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan. [PDF]

Transl Oncol
Pourjamal N, Le Joncour V, Vereb G, Honkamaki C, Isola J, Leyton JV, Laakkonen P, Joensuu H, Barok M.   +8 more
europepmc   +1 more source

From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression. [PDF]

Front Pharmacol, 2021
Chen Z, Yuan J, Xu Y, Zhang C, Li Z, Gong J, Li Y, Shen L, Gao J.   +8 more
europepmc   +1 more source

Sex hormone supplementation improves breathing and restores respiratory neuroplasticity following C2 hemisection in rats. [PDF]

Front Physiol
Barok R, Grittner JML, Miller S, Dougherty BJ.   +3 more
europepmc   +1 more source

Kultura muzyczna cystersów w Polsce od średniowiecza po barok

, 1995
Tadeusz Maciejewski
openalex   +2 more sources

Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model. [PDF]

Clin Exp Metastasis
Pourjamal N, Yazdi N, Halme A, Joncour VL, Laakkonen P, Saharinen P, Joensuu H, Barok M.   +7 more
europepmc   +1 more source

KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer. [PDF]

J Cancer Res Clin Oncol, 2023
Shimozaki K, Shinozaki E, Yamamoto N, Imamura Y, Osumi H, Nakayama I, Wakatsuki T, Ooki A, Takahari D, Ogura M, Chin K, Watanabe M, Yamaguchi K.   +12 more
europepmc   +1 more source

Nonclinical evaluation of HS630, a proposed biosimilar of trastuzumab emtansine: affinity, pharmacokinetics, and immunogenicity. [PDF]

Front Pharmacol
Jiang H, Che J.
europepmc   +1 more source

PKC-mediated phosphorylation and activation of the MEK/ERK pathway as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer. [PDF]

Front Endocrinol (Lausanne), 2022
Scerri J, Scerri C, Schäfer-Ruoff F, Fink S, Templin M, Grech G.   +5 more
europepmc   +1 more source